Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

scAAV1.tMCK.NTF3 - Nationwide Children's Hospital/Sarepta Therapeutics

Drug Profile

scAAV1.tMCK.NTF3 - Nationwide Children's Hospital/Sarepta Therapeutics

Alternative Names: AAV1.NT-3 gene therapy - Nationwide Children's Hospital; Neurotrophin-3 gene therapy - Nationwide Children's Hospital; rAAV1.NT-3 gene therapy - Nationwide Children's Hospital

Latest Information Update: 12 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nationwide Children's Hospital
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Charcot-Marie-Tooth disease

Most Recent Events

  • 27 May 2019 Sarepta Therapeutics plans a clinical trial for Charcot-Marie-Tooth disease in 2019
  • 08 Oct 2018 Nationwide Children’s Hospital and Sarepta Therapeutics enter an option agreement for neurotrophin-3 gene therapy for the treatment of Charcot-Marie-Tooth disease
  • 01 Oct 2018 Phase-I/II clinical trials in Charcot-Marie-Tooth disease (In adolescents, In adults) in USA (IM) (NCT03520751)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top